| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 58.081 | 98.181 | 118.891 | 125.340 | 142.718 | 134.169 | 156.242 |
| Total Income - EUR | - | - | 0 | 70.259 | 101.934 | 123.386 | 128.584 | 145.060 | 136.283 | 158.617 |
| Total Expenses - EUR | - | - | 1.648 | 64.854 | 97.511 | 122.782 | 123.633 | 133.854 | 130.589 | 157.441 |
| Gross Profit/Loss - EUR | - | - | -1.648 | 5.405 | 4.423 | 604 | 4.951 | 11.206 | 5.694 | 1.176 |
| Net Profit/Loss - EUR | - | - | -1.648 | 4.824 | 3.491 | -367 | 3.722 | 10.052 | 4.529 | 527 |
| Employees | - | - | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Brimed Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 6.831 | 26.657 | 22.168 | 18.532 | 11.773 | 8.757 | 7.599 | 4.765 |
| Current Assets | - | - | 1.338 | 27.945 | 33.298 | 53.741 | 52.144 | 56.306 | 47.052 | 61.860 |
| Inventories | - | - | 178 | 11.870 | 18.668 | 30.253 | 29.547 | 29.814 | 26.563 | 34.005 |
| Receivables | - | - | 438 | 12.649 | 12.277 | 20.631 | 20.892 | 21.563 | 16.593 | 20.488 |
| Cash | - | - | 721 | 3.426 | 2.353 | 2.857 | 1.704 | 4.929 | 3.896 | 7.368 |
| Shareholders Funds | - | - | -1.604 | 3.249 | 6.677 | 6.183 | 9.768 | 19.850 | 21.566 | 21.972 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 9.773 | 31.006 | 32.478 | 53.378 | 44.770 | 37.958 | 27.885 | 41.515 |
| Income in Advance | - | - | 0 | 20.707 | 16.831 | 13.102 | 9.602 | 7.373 | 5.281 | 3.194 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Brimed Pharma Srl